#$ARWR Tweets

StockTwits

Arrowhead at a glance: (click here to show/hide)

Arrowhead - Press Releases and SEC Filings	Chart:	Clinical Trials:	Goals for 2016:	C. Anzalone on CNBC:	What is RNAi ?

widget @ surfing-waves.com

About Arrowhead Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics.
Targeting Innovation
Arrowhead Pharmaceuticals develops novel drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Lead Products
ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. It is the first clinical-stage drug candidate from Arrowhead’s Dynamic Polyconjugate® delivery platform. It is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins with the goal of achieving a functional cure for HBV.

ARC-AAT is a novel unlocked nucleobase analog (UNA)-containing RNAi-based therapeutic for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease that can severely damage the liver and lungs of affected individuals. The goal of treatment with ARC-AAT is to reduce the production of the mutant Z-AAT protein to prevent and potentially reverse accumulation-related liver injury and fibrosis.

The companys pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates.

Platform Delivery Technology
The Dynamic Polyconjugate (DPC®) platform is an RNAi delivery system that has been demonstrated to preferentially deliver to hepatocytes, induce efficient endosomal escape, promote high levels of gene knockdown in multiple animal models, and appears to be well tolerated using a variety of RNAi trigger molecules. It is a modular system that can be optimized on a target-by-target basis and may be targeted in the future to address multiple organ systems and cell types.

Pipeline Development Strategy
Arrowhead’s internal drug pipeline is intended to drive value directly through the clinical development of novel therapeutics and to provide proof of concept for our platform technologies. In addition to our two lead product candidates, ARC-520 and ARC-AAT, we intend to nominate additional clinical candidates that utilize the DPC delivery system. Our core areas of focus for expanding our internal pipeline of RNAi therapeutics are: (1) develop intravenous (IV) administered liver-targeted candidates; (2) develop subcutaneously administered liver-targeted candidates; and (3) explore extra-hepatic targets, including oncology.

To learn more about Arrowhead visit the company's website at: http://arrowheadpharma.com/

Reply

ARWR Dead in the water until rid of CA....

« Prev
1
Next »

ARWR New Member

Posts: 46

Registered: Nov 25, 2015 9:17:55 GMT -5

ARWR Dead in the water until rid of CA.... Jan 5, 2017 1:27:57 GMT -5

Quote

Post by mudbug021 on Jan 5, 2017 1:27:57 GMT -5

As I have always insisted, know what you are invested in! see you in a couple of years... this is the pharmacy business!

(fyi, blaming management is a simplistic way of justifying your investment.. maybe you should look in the mirror to find blame.. or maybe you might see investron?)

[Go to Top] [Go to Bottom]

tmak

ARWR New Member

Posts: 8

Registered: Nov 30, 2015 8:04:02 GMT -5

ARWR Dead in the water until rid of CA.... Feb 9, 2017 11:16:41 GMT -5 qbeing1010 likes this

Quote

Post by tmak on Feb 9, 2017 11:16:41 GMT -5

hi mud,

i'm not sure what arwr traded at on january 5th...but i believe you may have missed a run-up from that date until now..i took a six figure haircut in november, but i held my nose and bought more shares in early december..i agree that the company's value will not be reflected for several years...but i still believe it is under-valued at $2, and one more deal like the amgn partnership will underline that point. also milestone payments by amgn should/could aded value in 2017....always value your input.

t

[Go to Top] [Go to Bottom]

ARWR New Member

Posts: 46

Registered: Nov 25, 2015 9:17:55 GMT -5

ARWR Dead in the water until rid of CA.... Feb 20, 2017 23:28:35 GMT -5

Quote

Post by mudbug021 on Feb 20, 2017 23:28:35 GMT -5

Hello, tmak.

To expand on my comment, the science is still there. The issue still lies in the delivery of it.

Just because Amgen is still invested doesnt imply ARWR knows what they are doing. Amgen is doing nothing more then what the rest of us are doing, taking a chance.

The simple fact is, if Amgen doesnt see results in the next 4 years(or sooner) they will pull out and take their losses(they can afford it)

[Go to Top] [Go to Bottom]

Latest videos from CNBC: